1 month AMGN Stock Down Despite Strong Data From Obesity Drug Study Zacks

Data from a phase II study shows that AMGN’s obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.

Amgen (AMGN)